Partha Anbil explores the current state of AI agents in drug discovery, with a specific focus on clinical data harmonisation, the transition to autonomous laboratories, and the projected market growth that underscores this technological revolution. Introduction: The dawn of agentic AI Drug discovery is notoriously protracted, expensive,… Read More
The global informatics market is expected to triple in size in the next ten years. These technologies are speeding up the process of drug development, but also enabling better accuracy, more precision, more reproducibility and ultimately, better science. This eBook explores the latest developments in artificial… Read More
This eBook explores the latest developments in artificial intelligence (AI), computational models and quantum computing that are driving drug discovery today.
Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, has secured £1.3 million ($1.7 million) in funding to accelerate the commercialisation of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform. VivoScan is unique in providing HTS for drug discovery in a… Read More
The UK’s first high-security robotic AI laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases has opened in Liverpool. The £20 million Liverpool Accelerate Laboratory has been developed through the Infection Innovation Consortium: iiCON, which advances pioneering infection R&D through collaboration between industry, researchers and the NHS. It… Read More
Pharmaceutical company GSK has announced a strategic collaboration with the biotech Relation to improve the understanding of disease biology and support the discovery of new therapeutic targets. Specifically, the partnership will focus on generating large-scale human cellular perturbation data and deploying them into models, such as Relation’s… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration. The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
Applications have opened for a national accelerator programme supporting data-driven health innovation. KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine. … Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
Anthropic has launched Claude Science, an app that it says integrates the tools and packages that researchers most commonly use, produces auditable artifacts, and provides flexible access to computing resources. At the launch event, the company also announced that it will be using the product to pursue… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
In drug discovery, valuable scientific insights are often scattered across spreadsheets, slide decks and email threads. Chemistry teams spend hours preparing for update meetings, chasing CRO progress and digging into the data to find out what has been done before. When hypotheses and learnings only live in slides or individual… Read More
By Sandy Tammisetty, VP of the Veeva Services Practice Group at Conexus Solutions. Artificial intelligence (AI) is no longer a future concept in clinical trials. It is already influencing how clinical data is reviewed, monitored, and analysed, particularly as trials become more complex and data volumes continue to grow. From anomaly detection to… Read More
